Neuroscience

#Financing #Funding #MapLight Therapeutics #Neuroscience

MapLight Therapeutics makes $372.5m in series D financing

MapLight Therapeutics has announced an oversubscribed $372.5 million Series D financing.   The financing was co-led by Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional new investors, including Sanofi, accounts advised by T Rowe Price Investment Management, Inc. and Avego BioScience Capital.   The financing also included strong… Read More

#Business & Investment #News

Drugs targeting amyloid Plaque
#Alzheimer's #Neuroscience #Phase III trial #Roche

Roche’s AD study shows rapid clearance of amyloid plaques

Roche has shared new data from its Alzheimer’s development portfolio at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada.  Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle Alzheimer’s disease (AD) study and design of the Phase III TRONTIER 1 and 2… Read More

#Editor's Choice #News

Neurons
#Amyotrophic lateral sclerosis (ALS) #Biogen #MHRA #MND #Neuroscience

First new ALS treatment approved in UK in 30 years

Biogen’s Qalsody (tofersen) has been approved in the UK as the first therapy to treat a rare, genetic form of amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND).  The Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation for tofersen through the International Recognition Procedure (IRP)… Read More

#News #Regulatory #Trending News

#Artificial intelligence (AI) #Neuroscience #Supercomputing

How advances in neuroscience can be powered by AI and supercomputing

DDW Editor Reece Armstrong sits down with Tarek Samad, Lundbeck’s Senior Vice President and Head of Research to discuss AI and supercomputing within the drug discovery industry following the company’s recent agreement with the Danish Centre for AI Innovation (DCAI). In May this year, Lundbeck announced an agreement with the… Read More

#Exclusive Content

Brain inflammation
#Neuroinflammation #Neuroscience #Preclinical development #ReAlta

Pegtarazimod reduces brain inflammation, says new study data

A new study has shown that pegtarazimod reduces microglial activation associated with pathogenic neuroinflammation in hypoxic ischaemic encephalopathy (HIE), as well as neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.  The article in the American Journal of Perinatology highlights that pegtarazimod reduces… Read More

#News

#Alzheimer's #Gene therapy #Neuroscience #Voyager Therapeutics

Voyager adds fourth Alzheimer’s disease programme to pipeline

Voyager Therapeutics has added a new programme that modulates the expression of apolipoprotein E (APOE), the strongest genetic risk factor for Alzheimer’s disease (AD).  The programme uses a proprietary intravenous (IV)-delivered, blood-brain barrier (BBB)-penetrant TRACER capsid to deliver a bifunctional payload that is designed to decrease expression… Read More

#News

Neuroscience
#Assays #Guide #iPSC #Neuroscience #Preclinical development

Guide: 10 practical tips for reliable MEA experiments in preclinical neuroscience

Combining human iPSC-derived neurons with multi-electrode array (MEA) assays can provide powerful insights into synaptic connectivity, network dynamics, and functional maturation. However, MEA experiments can be challenging, with small changes in cell culture conditions dramatically impacting results. In this expert Guide, bit.bio’s Field Applications Scientist shares key considerations for improving… Read More

#News

#Assays #iPSC #Neuroscience #Preclinical development

10 practical tips for reliable MEA experiments in preclinical neuroscience

Combining human iPSC-derived neurons with multi-electrode array (MEA) assays can provide powerful insights into synaptic connectivity, network dynamics, and functional maturation. However, MEA experiments can be challenging, with small changes in cell culture conditions dramatically impacting results. In this expert Guide, bit.bio’s Field Applications Scientist shares key considerations for improving… Read More

#Resources

Human neuron
#Age-related diseases (ARDs) #Artificial intelligence (AI) #Biochemistry #Biotechnology #Integrated Biosciences #Neuroscience #Optogenetics

New optogenetic screening platform for drug discovery

Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases, has published a study in Cell, introducing its optogenetic screening platform. According to the paper, the platform allows for precise and dynamic control of biological targets and processes, unlocking a powerful new… Read More

#News

#Neuroscience

Guide – 10 Practical Tips for Reliable MEA Experiments in Preclinical Neuroscience

Combining human iPSC-derived neurons with multi-electrode array (MEA) assays can provide powerful insights into synaptic connectivity, network dynamics, and functional maturation. However, MEA experiments can be challenging, with small changes in cell culture conditions dramatically impacting results. In this expert guide, bit.bio’s Field Applications Scientist shares key considerations for improving… Read More

#Guides

Neurons
#Alzheimer's #Collaboration #Enhanced Genomics #Genetics / genomics #Multi-omics #Neuroscience #University of Cambridge

Genomics partnership discovers novel targets for Alzheimer’s

Biotechnology company Enhanced Genomics has announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge.   Funded by Alzheimer’s Research UK, The ALBORADA Drug Discovery Institute is developing the next generation of treatments for the diseases that cause dementia.   The partnership… Read More

#News

Degeneration of dopaminergic neuron in Parkinson's disease
#Amyotrophic lateral sclerosis (ALS) #Dementia #Longitude P #MND #Motor neuron disease #Neuroscience

Award transforming drug discovery with AI

The Longitude Prize on ALS is a new £7.5 million ($10.28 million) global challenge prize to incentivise and reward cutting edge AI-based approaches to transform drug discovery for the treatment of amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND). Open for entries from 25 June… Read More

#News

#Alzheimer's #Cellular imaging #Drug discovery #Imaging #Japan #Nanobodies #Neuroscience

Nanobody-based 3D imaging boosts neuroscience research

Scientists have created a nanobody-based method that enables ultra-fast, high-resolution 3D mapping of neurons and glia in thick brain tissues.  The researchers from Japan have developed a fast, high-sensitivity three dimensional immunohistochemistry (3D-IHC) method using nanobodies fused with peroxidase and a novel signal amplification system.  … Read More

#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Eisai #National Institute for Health and Care Excellence (NICE) #Neuroscience

NICE rejects Alzheimer’s drugs for lack of cost-effectiveness

The UK National Institute for Health and Care Excellence (NICE) has reached its final decision on two Alzheimer’s treatments, denying their use on the NHS due to the therapies not providing “good value for money.”  Eli Lilly’s donanemab and Eisai’s lecanemab were under final draft guidance by NICE, which had… Read More

#News #Regulatory #Trending News

Research scientists in laboratory
#Arialys Therapeutics #Autoimmune disease #Neuropsychiatric disorders #Neuroscience #Preclinical investigations #Therapeutic Antibodies

Study supports monovalent antibody in neuropsychiatric disease

New preclinical data have demonstrated that Arialys Therapeutics’ lead drug candidate, ART5803, effectively blocks the underlying disease mechanism in anti-NMDA receptor encephalitis (ANRE) and rapidly reverses behavioural symptoms in a non-human primate model.   The company says the findings support the continued clinical development… Read More

#Editor's Choice #News

Brain neurons in lysosomal storage diseases
#Casma Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's

Casma takes a new therapeutic approach to neurodegeneration

Casma Therapeutics has nominated its first development candidate, CSM-101, a first-in-class TRPML1 agonist, marking a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases.  CSM-101 is being developed for the treatment of Gaucher’s disease patients with Parkinson’s disease (GD-PD), with the potential to expand… Read More

#News